{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:55:57Z","timestamp":1740167757056,"version":"3.37.3"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Med"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s40290-024-00535-w","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T08:11:55Z","timestamp":1724400715000},"page":"373-380","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of the Effectiveness of Additional Risk Minimization Measures for Ixazomib Citrate for Relapsed\/Refractory Multiple Myeloma in Japan: A Web-Based Survey Among Pharmacists"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6115-2755","authenticated-orcid":false,"given":"Yoshiko","family":"Maeda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8799-5438","authenticated-orcid":false,"given":"Akihito","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1501-9981","authenticated-orcid":false,"given":"Seigo","family":"Seki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0826-1358","authenticated-orcid":false,"given":"Nobuhiro","family":"Narii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7738-1970","authenticated-orcid":false,"given":"Yasuhiro","family":"Katsura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2394-3556","authenticated-orcid":false,"given":"Yukiko","family":"Muramatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2310-6812","authenticated-orcid":false,"given":"Motonobu","family":"Sakaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,21]]},"reference":[{"key":"535_CR1","unstructured":"European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) Module XVI-Risk minimization measures: selection of tools and effectiveness indicators (Rev 3). 2021. https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/guideline-good-pharmacovigilance-practices-gvp-module-xvi-risk-minimisation-measures-selection-tools-and-effectiveness-indicators-rev-3_en.pdf. Accessed 21 Mar 2024."},{"key":"535_CR2","unstructured":"US Food and Drug Administration. REMS Assessment: Planning and Reporting Guidance for Industry (draft guideline). 2019. https:\/\/www.fda.gov\/media\/119790\/download. Accessed 21 Mar 2024."},{"key":"535_CR3","unstructured":"US Food and Drug Administration. Survey methodologies to assess REMS goals that relate to knowledge guidance for industry (draft guideline). 2019. https:\/\/www.fda.gov\/media\/119789\/download. Accessed 21 Mar 2024."},{"issue":"6","key":"535_CR4","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/pds.5012","volume":"29","author":"E Artime","year":"2020","unstructured":"Artime E, Kahlon R, M\u00e9ndez I, et al. Linking process indicators and clinical\/safety outcomes to assess the effectiveness of abatacept (ORENCIA) patient alert cards in patients with rheumatoid arthritis. Pharmacoepidemiol Drug Saf. 2020;29(6):664\u201374. https:\/\/doi.org\/10.1002\/pds.5012. (Epub 2020 May 12).","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"535_CR5","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s40264-018-0662-2","volume":"41","author":"W Landsberg","year":"2018","unstructured":"Landsberg W, Al-Dakkak I, Coppin-Renz A, et al. Effectiveness evaluation of additional risk minimization measures for adolescent use of aripiprazole in the European Union: results from a post-authorization safety study. Drug Saf. 2018;41(8):797\u2013806. https:\/\/doi.org\/10.1007\/s40264-018-0662-2.","journal-title":"Drug Saf"},{"issue":"2","key":"535_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s40290-019-00273-4","volume":"33","author":"J Lem","year":"2019","unstructured":"Lem J, Younus M, Aram JA, et al. Evaluation of the effectiveness of additional risk minimization measures for voriconazole in the EU: findings and lessons learned from a healthcare professional survey. Pharm Med. 2019;33(2):121\u201333. https:\/\/doi.org\/10.1007\/s40290-019-00273-4.","journal-title":"Pharm Med."},{"issue":"3","key":"535_CR7","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40801-018-0140-2","volume":"5","author":"J Ascher","year":"2018","unstructured":"Ascher J, Stemhagen A, Stender M, et al. Patient understanding of the neuropsychiatric risks associated with branded bupropion hydrochloride products used for smoking cessation. Drugs Real World Outcomes. 2018;5(3):181\u201391. https:\/\/doi.org\/10.1007\/s40801-018-0140-2.","journal-title":"Drugs Real World Outcomes."},{"issue":"3","key":"535_CR8","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/pds.4373","volume":"27","author":"KL Amend","year":"2018","unstructured":"Amend KL, Younus M, Petronis KR, et al. Assessment of risk evaluation and mitigation strategies (REMS) for varenicline (Chantix): a multistage patient survey. Pharmacoepidemiol Drug Saf. 2018;27(3):253\u201362. https:\/\/doi.org\/10.1002\/pds.4373. (Epub 2018 Feb 6).","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"535_CR9","unstructured":"Directors of Safety Division and Director of Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare. Risk management plan guidance. 2012. https:\/\/www.pmda.go.jp\/files\/000153333.pdf. Accessed 21 Mar 2024."},{"issue":"3","key":"535_CR10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.14982\/rsmp.10.87","volume":"10","author":"M Narukawa","year":"2020","unstructured":"Narukawa M, Yamada T. Evaluation of the effectiveness of additional risk minimization activities in the Risk Management Plan (RMP): internet survey on the effect of information materials for patients -Xofluza as an example (in Japanese). Regulat Sci Med Prod. 2020;10(3):87\u201398. https:\/\/doi.org\/10.14982\/rsmp.10.87.","journal-title":"Regulat Sci Med Prod"},{"key":"535_CR11","unstructured":"NIKKEI RESEARCH INC. Characteristics of Nikkei Medical Online Panel. https:\/\/service.nikkei-r.co.jp\/service\/healthcare\/medical-healthcare. Accessed 21 Mar 2024."},{"issue":"4","key":"535_CR12","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s40264-020-01033-z","volume":"44","author":"R Mouchantaf","year":"2021","unstructured":"Mouchantaf R, Auth D, Moride Y, et al. Risk management for the 21st century: current status and future needs. Drug Saf. 2021;44(4):409\u201319. https:\/\/doi.org\/10.1007\/s40264-020-01033-z. (Epub 2021 Feb 9).","journal-title":"Drug Saf"},{"key":"535_CR13","unstructured":"Ministry of Health, Labour and Welfare. Listings of the designated center care hospitals for cancer. 2023. https:\/\/www.mhlw.go.jp\/content\/001119147.pdf. Accessed 21 Mar 2024."},{"issue":"44","key":"535_CR14","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000027589","volume":"100","author":"A Okahashi","year":"2021","unstructured":"Okahashi A, Kobayashi M, Okuyama K, et al. Survey of physician knowledge of congenital cytomegalovirus infection and clinical practices in Japan: a web-based survey. Medicine (Baltimore). 2021;100(44): e27589. https:\/\/doi.org\/10.1097\/MD.0000000000027589.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"535_CR15","doi-asserted-by":"publisher","first-page":"22789","DOI":"10.1038\/s41598-021-02319-7","volume":"11","author":"D Inoue","year":"2021","unstructured":"Inoue D, Yamamoto M, Arima H, et al. A nationwide web-based survey of oncologic surgeons to clarify the current status of preoperative assessment for elderly cancer surgery patients in Japan. Sci Rep. 2021;11(1):22789. https:\/\/doi.org\/10.1038\/s41598-021-02319-7. (Erratum in: Sci Rep. 2023 Jun 15;13(1):9705).","journal-title":"Sci Rep"},{"key":"535_CR16","unstructured":"Japan Pharmaceutical Manufacturers Association. Comparative survey on the status of additional risk minimization activities in the risk management plan (RMP) among Japan, the U.S., and Europe (in Japanese). 2023. https:\/\/www.jpma.or.jp\/information\/evaluation\/results\/allotment\/bbh7c90000001dic-att\/PV_202311_aRMMs.pdf. Accessed 21 Mar 2024."}],"container-title":["Pharmaceutical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-024-00535-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40290-024-00535-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-024-00535-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T15:05:58Z","timestamp":1728918358000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40290-024-00535-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,21]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["535"],"URL":"https:\/\/doi.org\/10.1007\/s40290-024-00535-w","relation":{},"ISSN":["1178-2595","1179-1993"],"issn-type":[{"type":"print","value":"1178-2595"},{"type":"electronic","value":"1179-1993"}],"subject":[],"published":{"date-parts":[[2024,8,21]]},"assertion":[{"value":"5 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Funding of this survey was provided by Takeda Pharmaceutical Company Limited. The open access fee was provided by Takeda Pharmaceutical Company Limited.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors are full-time employees of Takeda Pharmaceutical Company Limited.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The data that supports the findings of this study are available from the corresponding author upon reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"All procedures in this survey complied with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The survey was reviewed and approved by the Ethics Committee of Kitamachi Clinic (May 17, 2023, TKD09522).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Persons participating in the study were informed of the targets of the investigation, the intended use of data, and recipients of these data.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed, critically reviewed drafts of the manuscript and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}